Cascades Inc. · TSX:CAS

Cascades — Q1 2024 Earnings Presentation

31 slides from Cascades's earnings presentation, May 9, 2024

  1. Slide 1: Q1 2024 Financial Results

    Q1 2024 FINANCIAL RESULTS May 9, 2024 Cascades Source of possibilities

  2. Slide 2: Forward-looking statements and non-GAAP measures

    !+$!%* '*/* $''#!&+,,%&, 9FH5=BGH5H9A9BHG=BH<=GDF9G9BH5H=CB =B7@I8=B;GH5H9A9BHGF9;5F8=B;:IHIF9F9GI@HG5B8D9F:CFA5B79 5F9:CFK5F8 @CC?=B;GH5H9A9BHGK=H<=BH<9A95B=B;C:G97IF=H=9G@9;=G@5H=CB65G98CB7IFF9BH9LD97H5H=CBG /<9577IF57MC:GI7<GH5H9A9BHG=GGI6>97HHC5BIA69FC:F=G?G IB79FH5=BH=9G5B85GGIADH=CBGH<5H A5M75

  3. Slide 3: Summary of Results

    +-%%*1'!&&!$*+-$,+ !?>:==:@?D@7& 6I46AEA6C4@>>@?D92C62>@F?ED H96C6?@E65 ) ) ) $,% :?2?4:2=*6DF=ED +2=6D *D9F5H=B;=B7CA9@CGG 5;FDE6562C?:?8D367@C6:?E6C6DE E2I6D 56AC64:2E:@?2?52>@CE:K2E:@?!,M (5F;=B $/ .5@9G &6E=@DD 8>IGH98B9H95FB=B;G@CGG Q &6E=@DDA6C4@>>@?D92C6 8>IGH98B9H95FB=B;G@CGGD9F7CAACBG<5F9 Q

  4. Slide 4: Consolidated EBITDA

    '.*.!/''&+'$!,(*'!,!$!,1*!.*+ @?D@=:52E65!, .2C:2E:@? )F2CE6C @G6C )F2CE6C 162C @G6C 162C :?>:==:@?D@72?25:2?5@==2CD ) GD) ) GD) +F=7=B; A=@@=CB A=@@=CB !F9=;<H+FC8I7H=CBCGHG A=@@=CB A=@@=CB 1C@IA9(=L !3*H<9FG A=@@=CB A=@@=CB -5K(5H9F=5@G B9F;M A=@@=CB QA=@@=CB ,',$ >:==:@? >:==:@? +@95G97@=7?<9F9:C

  5. Slide 5: Market Overview

    *1$!*'+,+ !&0$!+,(*!+ 0.G H FCC6?E ' AC P .HFCB; 8CA9GH=7 89A5B8 =B7@I8=B; ;FCK=B; @9J9@G :CF B9K F97M7@98 7CBH5=B9F6C5F8 A=@@G 69=B; F5AD98 ID :=6F9 ;9B9F5H=CB F9:@97H98 @CK9F G95GCB5@ ;9B9F5H=CB 5B8 GC:H9F 97CBCA=79BJ=FCBA9BH7CBG=GH9BH9LDCFH89A5B8 P /=;<H9FA5F?9H8MB5A=7G;=J9B:57HCFG56CJ9@98HCCB;C=

  6. Slide 6: Private Label and Paper

    .!*!&(-$('+,+ !&0$!+,(*!+ .!*!&(-$( 0.A9HF=7HCB FCC6?E P .9EI9BH=5@DF=79=B7F95G9G8F=J9B6MAI@H=D@9:57HCFG AC P ).&A=@@8CKBH=A9 D9FA5B9BH7@CGIF9G=B) P +CFH GHF=?9 5B8 IBD@5BB98 A=@@ 8CKBH=A9 =B !=B@5B8 F98I798 HF5::=7 =B ?9M G<=DD=B; FCIH9G 5@GC <=B89F98 @C;=GH=7G 5G8=85@H=ACF96F=8;97C@@5DG9 P (5H9F=5

  7. Slide 7: Comments on Sequential Performance

    (#!&(*'-,+ '&,!&*'* @>>6?ED@?D6BF6?E:2=A6C7@C>2?46 , , , /CH5@ G<=DA9BHG =B7F95G98 6M G9EI9BH=5@@M .<=DA9BHG C: D5F9BH FC@@G =B7F95G98 6M 5B8H<CG9C:7CBJ9FH98DFC8I7HG897F95G986M7CAD5F98HCH<9:CIFH<EI5FH9F +9:A>6?EDP D E 6CH<C:K<=7<5F9F9:@97H=J9C:IGI5@G95GCB5@HF9B8G /<9 5J9F5;9 :=FGH EI5FH9F G9@@=B; DF

  8. Slide 8: Quarterly EBITDA and segment results

    (#!&(*'-,+ '&,!&*'* )F2CE6C=J!, () .9EI9BH=5@,G<=DA9BHGC:7CBJ9FH98DFC8I7HG 2?252 JG A5F?9H -+ JG A5F?9H 495F CJ9F M95F,G<=DA9BHGC:7CBJ9FH98DFC8I7HG 2?252 JG A5F?9H -+ JG A5F?9H +57?5;=B;G<=DA9BHG85M ) ) JG 5B58=5BA5F?9H 0.A5F?9H ) ) ) ) ) ) ) JG 5B58=5BA5F?9H 0.A5F?9H $/ $/.5@9G )F2CE6C=J+2=6D2?5G6C

  9. Slide 9: Comments on sequential performance

    (#!&(*'-,+ +(!$,1(*'-,+ @>>6?ED@?D6BF6?E:2=A6C7@C>2?46 , , , +2=6D% .5@9GK9F9GH56@9G9EI9BH=5@@M K=H<(CI@898+I@DD57?5;=B;DFC8I7HG69B9:=H=B; Q :FCA<=;<9FG9@@=B;DF=79G5B85:5JCF56@9DFC8I7HA=L C::G9H6M@CK9FJC@IA9 $B 588=H=CB H<9 5DDF97=5H=CB C: H<9 5B58=5B 8C@@5F 7CAD5F98 HC H<9 0. 8C@@5F B9;5H=J9@M=AD57

  10. Slide 10: Quarterly EBITDA and segment results

    (#!&(*'-,+ +(!$,1(*'-,+ )F2CE6C=J!, () 2C53@2C5 F9GI@HG =B7F95G98 G9EI9BH=5@@M F9:@97H=B; GHFCB;9F JC@IA9 5B8@CK9F@56CIF HF5BGDCFH5B89B9F;M7CGHG D5FH=5@@M C::G9H6M<=;<9FF5KA5H9F=5@5B8:=L987CGHG %@F=565 AF=A GC:H9F G9EI9BH=5@ F9GI@HG 8F=J9B 6M <=;<9F F5K A5H9F=5@ 7CGHG @CK9F JC@IA9G 5B8 <=;<9F DFC8I7

  11. Slide 11: Cases sold (millions) - comments on sequential performance

    ,!++-((*+ @>>6?ED@?D6BF6?E:2=A6C7@C>2?46 , , , .<=DA9BHG 897F95G98 6M CB 5 G9EI9BH=5@ 65G=G K5M :FCA #CA9 7CBJ9FH98 DFC8I7H +9:A>6?EDP D E G<=DA9BHG 897F95G98 6M =B H<9 :=FGH EI5FH9F K<=@9 H<CG9 C: F9H5=@ DFC8I7HG G@=;<H@M =B7F95G98 G6C286D6==:?8AC:46 /<9 5J9F5;9 G9@@=B; DF=79 897F95G98 6M G9EI9BH=5

  12. Slide 12: Segments of converted products

    ,!++-((*+ )F2CE6C=J!, () ) +9:A>6?ED@7@?G6CE65(C@5F4ED *6E2:=E:DDF6 H2J 7C@> @>6E:DDF6 %42D6D %42D6D ,JG, ,JG , ,JG , ,JG , ) ) ) ) ) $/ $/.5@9G )F2CE6C=J+2=6D2?5G6C286+6==:?8(C:46 )F2CE6C=J+9:A>6?ED TG H 5B875D57=HMIH=@=N5H=CB ) ) ) ) ) ) ) ) ) ) .5@9G() J9F5;9G9@@=B;DF=79) +@95G97@=7?<9F9:CFGIDD@9

  13. Slide 13: Unrealized gains on financial instruments

    ) !,,''(*,!&!&'%*'&!$!,!'& () $/ 0BF95@=N98;5=B $AD5=FA9BH *H<9F@CGG -9GHFI7HIF=B; 9DF *D9F5H=B;=B7CA9 CB:=B5B7=5@ 7<5F;9G 7CGHG ACFH =BGHFIA9BHG CFDCF5H9 -97CJ9FM5B8 CBH5=B9F .D97=5@HM /=GGI9 -97M7@=B; () 6C5F8 +FC8I7HG +5D9FG 57H=J=H=9G ,@E2= 'A6C2E:?8:?4@>6=@DD 9DF97=5H=CB5B85ACFH=N5H=CB $AD5=FA9

  14. Slide 14: Income taxes

    &,$'++ +*('*,GD"-+, &,$'++ &,$'++ (*'%%'&+ * !?>:==:@?D@72?25:2?5@==2CD 6I46AEA6C4@>>@?D92C62>@F?ED ) ) DC6A@CE65 .D97=:=7=H9AG -9GHFI7HIF=B;7CGHG *H<9F@CGG $AD5=FA9BH7<5F;9G !CF9=;B9L7<5B;9@CGGCB@CB; H9FA896H:=B5B7=5@=BGHFIA9BHG 0BF95@=N98;5=BCB:=B5B7=5@=BGHFIA9BHG 0BF95@=N98;5=BCB=BH9F9GHF5H9GK5DG

  15. Slide 15: Comments

    )-*,*$11* '.* 1*"-+,(+.*!& Q 79BHG +.F9DCFH98 .D97=:=7 8>IGH98 +. )CB $B7CA9H5L 9DF97=5H=CB !=B5B7=B; $/ 8>IGH98 +. .D97=:=7 +.F9DCFH98 , =H9AG , 7CBHFC@@=B; J5F=5B79 9LD9BG9 , =H9AG , =BH9F9GHG 5ACFH=N5H=CB :H9F H5LJ5F=5B79BCFA5@=N985HH5LF5H9 9L79DH:CF$B7CA9H5LJ5F=5B797C@IAB +@95G97@=7?<9F9:CFGIDD@

  16. Slide 16: Comments

    )-*,*$1+)-&,!$"-+,(+.*!& O 79BHG +.F9DCFH98 .D97=:=7 8>IGH98 +. 9DF97=5H=CB $B7CA9 )CB .<5F9C: !=B5B7=B; $/ 8>IGH98 +. .D97=:=7 +.F9DCFH98 , =H9AG , H5L 7CBHFC@@=B; F9GI@HGC: 9LD9BG9 , =H9AG , 5ACFH=N5H=CB J5F=5B79 =BH9F9GHG %1G5B8 5GGC7=5H9G :H9F H5LJ5F=5B79BCFA5@=N985HH5LF5H9 9L79DH:CF$B7CA9H5LJ5F

  17. Slide 17: Year over year increase in adjusted cash flow

    + $'/'.*.!/ !?>:==:@?D@7& 6I46AEA6C4@>>@?MD92C62>@F?ED ) ) ) ) 162C ) ) ) ) 162C ) 5G<:@CK:FCACD9F5H=CBG .D97=:=7=H9AG Q 8>IGH9875G<:@CK:FCACD9F5H=CBG ! " +5MA9BHG:CFDFCD9FHM D@5BH5B89EI=DA9BHCH<9F 5GG9HG @95G9C6@=;5H=CBGD5MA9BHG B9HC:8=GDCG5@G =J=89B8G 8>IGH9875G<:@CK;9B9F5H98IG98 8>IGH9875G<:@CK;9

  18. Slide 18: 2024 Forecast

    &/(!,$!&.+,%&,+ :?>:==:@?D@72?25:2?5@==2CD 6I4=F5:?8?6H=62D6D 5:DA@D2=@72DD6ED2?5244@F?EDA2J23=6G2C:2E:@? !CF975GH L % ) @?E2:?6C3@2C5 +A64:2=EJ(C@5F4ED ,:DDF6(2A6CD @CA@C2E6 *64@G6CJ2?5*64J4=:?8 ACIBH=GGI6>97HHC7<5B;989D9B8=B;CB6IG=B9GG5B8CF97CBCA=77CB8=H=CBG

  19. Slide 19: Net debt to consolidated profitability levels

    &,,*'&!$!,!'& ) () )9H896H5GC: 5G<:@CK -=;<H C: IG9 =J=89B8GD5=8 !3) +5MA9BHG:CFDFCD9FHM <5B;9G=BBCB 75G< )9H896H5GC: 979A69F :FCACD9F 5GG9HG57EI=G=H=CBG 7<5B;9=B75D=H5@ D@5BH5B89EI=DA9BH KCF?=B;75D=H5@ (5F7< 57H=J=H=9G GHC7? 7CADCB9BHG ) ) A=@@=CB '/( $/ A=@@=CB L )9H896H'/( $/F5H=C L :896C=6G6C286

  20. Slide 20: Net debt / EBITDA

    '&+'$!,!&&!$*,!'+,%,-*!,!+ &6E63E !, !?E6C6DE@G6C286*2E:@ L L L L L L L I L L L L L L L L L L I L ) ) &6E63E &6E63E,@E2=BF:EJ $@?8 ,6C>63E%2EFC:E:6D J62C J62C "2? ) -9JC@J=B;7F98=H 0BG97IF98G9B=CFBCH9G :57=@=HM /9FA@C5B '95G9G .I6G=8=5F=9G 2=H<CIHF97CIFG9 96HGK=H<CIHF97CIFG9 .I6G=8=5F=9G896HG "F99BD

  21. Slide 21: Assumes current index prices

    &*,*%,'*+ ) !,,*&GD ) DDF>6D4FCC6?E:?56IAC:46D P .HFCB;9FCBH5=B9F6C5F8F9GI@HG<=;<9FF5KA5H9F=5@DF=79G:CF5@@ '&+'$!, 6IG=B9GG9G Q #=;<9FG9@@=B;DF=79G5@=;B98K=H<=B89LACJ9A9BH GHFCB;9FJC@IA9 @?E2:?6C3@2C5 <=;<9FF5KA5H9F=5@CD9F5H=CB5@7CGHG Q .9@@=B;DF=79=B7F95G9G=BGCA96IG=B9GGG9;A9BHG5B869B9:=HG:FCA +A64

  22. Slide 22: Appendix

    APPENDIX

  23. Slide 23: Financial Results

    +-%%*1')-*,*$1!&&!$*+-$,+#(!D !?>:==:@?D@7& 6I46AEA6C4@>>@?D92C62>@F?ED H96C6?@E65 ) ) ) ) 162C ) ) ) ) 162C ) :?2?4:2=*6DF=ED +2=6D *D9F5H=B;=B7CA9@CGG 5;FDE6562C?:?8D367@C6:?E6C6DE E2I6D 56AC64:2E:@?2?5 2>@CE:K2E:@?!,M (5F;=B $/ .5@9G &6E62C?:?8D=@DD 8>IGH98B9H95FB=B;G@CGG Q &6E62C?:?8D=@DDA6C4@>>

  24. Slide 24: Containerboard, Specialty Products, Tissue Papers

    1* '.* 1*+$+*'&!$!,!'& %& *64@G6CJ +2=6D *64J4=:?8 +2=6D %& )M %:I .@=F>6 'E96C:E6>D 0& (C:46 ) CBH5=B9F6C5F8 Q Q Q .D97=5@HM+FC8I7HG Q Q Q /=GGI9+5D9FG Q CFDCF5H9 -97CJ9FM5B8 -97M7@=B;57H=J=H=9G @=A Q Q Q Q ,@E2=

  25. Slide 25: Favourable volume/sales mix, lower product production costs

    1* '.* 1*!,*'&!$!,!'& !5JCIF56@9JC@IA9G5@9GA=L @CK9F 'CK9FCFDCF5H957H=J=H=9G7CGHG DFC8I7H=CB7CGHG 'CK9FDFC8I7H=CB7CGHG@CGIF9G 'CK9FG9@@=B;DF=79 <=;<9FF5KA5H9F=5@ #=;<9FF9GI@HG:FCA-97CJ9FM 7CGHG 'CK9FF5KA5H9F=5@ @C;=GH=7G5B8 CD9F5H=CBG 9B9F;M7CGHG 'CK9FG9@@=B;DF=79G 'CK9FG9@@=B;DF=79G #=;<9FF5KA5H9F=

  26. Slide 26: Favourable volume/sales mix, lower product production costs

    +)-&,!$+$+*'&!$!,!'& %& *64@G6CJ +2=6D *64J4=:?8 +2=6D %& )M (C:46 'E96C:E6>D 0& .@=F>6 %:I )M CBH5=B9F6C5F8 Q .D97=5@HM+FC8I7HG Q Q /=GGI9+5D9FG Q CFDCF5H9 -97CJ9FM5B8 -97M7@=B;57H=J=H=9G @=A Q Q Q Q ,@E2=

  27. Slide 27: Power operating costs lower raw material

    +)-&,!$!,*'&!$!,!'& 'CK9FCD9F5H=CB5@7CGHG #=;<9FG9@@=B;DF=79 #=;<9FG9@@=B;DF=795B8@CK9F 'CK9FJC@IA9 'CK9FG9@@=B;DF=79G F5KA5H9F=5@7CGHG #=;<9FCD9F5H=CB5@7CGHG #=;<9FF5KA5H9F=5@ DFC8I7H=CB :F9=;<H5B89B9F;M7CGHG %& 'CK9FF9GI@HG:FCA-97CJ9FM CD9F5H=CBG 'CK9F7CGH:FCACFDCF5H957H=J=H=9G , 9DF .D97=:=7 , .D

  28. Slide 28: Cost of sales and selling and administrative expenses

    '+,'+$+ +$$!&&%!&!+,*,!.0(&++ !?>:==:@?D@72?25:2?5@==2CD ) ) ) @DE@7D2=6D -5KA5H9F=5@G 25;9G5B869B9:=HG B9F;M 9@=J9FM *H<9F 9DF97=5H=CB5B85ACFH=N5H=CB +6==:?82?525>:?:DEC2E:G66IA6?D6D 25;9G5B869B9:=HG $B:CFA5H=CBH97<BC@C;M DI6@=7=HM A5F?9H=B;5B8CH<9F

  29. Slide 29: Containerboard Selected Products

    +$,**&(*!+ FCC6?E FCC6?E @?E2:?6C3@2C5 +6=64E65(C@5F4ED 0.G H +A64:2=EJ(C@5F4ED +6=64E65(C@5F4ED AC 0.G H AC )CJ !96 (5M I; )CJ !96 !96 (5M I; )CJ !96 (5M I; )CJ !96 (5M I; )CJ !96 (5M I; )CJ !96 (5M I; )CJ !96 !96 (5M I; )CJ !96 (5M I; )CJ !96 (5M I; )CJ !96 (5M I; $:?6C3@2C5 @CCF82E:?8>65:F> -?4@2

  30. Slide 30: Selling price indices and earnings call

    +$,**&(*!+&!*'+,+ ) GD ) GD ) )M /<9G9 =B89L9G G<CI@8 CB@M 69 IG98 5G 5B =B8=75HCF C: HF9B8G 5B8 H<9M A5M 69 8=::9F9BHH<5BCIF57HI5@G9@@=B;DF=79GCFDIF7<5G=B;7CGHG , , , , 495F , , , , 495F ) F?:ED F?:ED +6==:?8(C:46D2G6C286 (#!&(*'-,+ @?E2:?6C3@2C5-+ D9@CEE@? '=B9F6C5F8 @6 IB6@957<98?F5:H 5GH9FB0.CD9

  31. Slide 31: For more information

    @C>@C6:?7@C>2E:@? KKK 75G7589G 7CA=BJ9GHCFG %9BB=:9F=H?9B ( =F97HCF $BJ9GHCF-9@5H=CBG =BJ9GHCF75G7589G 7CA

Cascades — Q1 2024 Earnings Presentation on 6ix